Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Gilead Sciences has announced a strategic partnership with Genesis Therapeutics, aimed at using AI to discover and develop ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $81.44 which represents a slight increase of $2.27 or 2.87% from the prior close of $79.17. The stock opened at $79.17 and ...

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...

Gilead Sciences (GILD) and Genesis Therapeutics have entered into a strategic collaboration to discover and develop small molecule ...

Gilead Sciences, Virtus Investment Partners and Hess Midstream have rewarded their shareholders for more than a decade and ... Johanna Mercier, Chief Commercial Officer of Gilead Sciences Inc ...

For those with $200 to spare that isn't being saved for emergencies, let's consider two healthcare stocks within that budget ...

Gilead Sciences’ shares closed up 2.7% at $83.16 yesterday, after it releases positive results of an interim analysis from a ...

Gilead Sciences, Inc. and Genesis Therapeutics, Inc. have announced that the companies have entered into a strategic ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule ...